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Recent technological advances have opened the door for
the fast and cost-effective generation of genetically engin-
eered mouse models (GEMMs) to study cancer. We
describe here a conceptually novel approach for the
generation of chimeric GEMMs based on the controlled
introduction of various genetic elements in embryonic
stem cells (ESCs) that are derived from existing mouse
strains with a predisposition for cancer. The isolation of
GEMM-derived ESC lines is greatly facilitated by the avail-
ability of the newly deﬁned culture media containing inhibi-
tors that effectively preserve ESC pluripotency. The
feasibility of the GEMM-ESC approach is discussed in light
of current literature and placed into the context of existing
models. This approach will allow for fast and ﬂexible vali-
dation of candidate cancer genes and drug targets and will
result in a repository of GEMM-ESC lines and correspond-
ing vector collections that enable easy distribution and use
of preclinical models to the wider scientiﬁc community.
Keywords: .cancer; chimeras; embryonic stem cell; genetically
engineered mouse model; non-germline models;
recombinase mediated cassette exchange
Introduction
Cancer is a disease in which cells display uncontrolled growth
accompanied by invasion into normal adjacent tissues. At
later stages, some cancers metastasize to other locations in
the body via lymph or blood circulation. Studies into the
underlying mechanisms have resulted in the identiﬁcation
of a number of key intracellular signaling pathways control-
ling cell growth and cell death that are often disrupted in
tumor cells [1]. Besides these cancer cell-intrinsic pathways
external factors also control tumor growth and behavior, e.g.
tumor angiogenesis, inﬁltrating immune cells, and activated
mesenchymal cells [2]. For these reasons many elements of
cancerbiology,includinginvasionandmetastasis,canonlybe
properly studied in the context of intact organisms. Early
attempts to model cancer in animals involved subcutaneous
or intravenous injection of established human tumor cell lines
into immunodeﬁcient mice and monitoring of local tumor
outgrowth. Although these xenograft models were effective
means to propagate human tumors, they did not model spora-
dic, de novo tumorigenesis in an immunologically competent
host. Over the years mouse models have become much
more sophisticated, particularly when genetically engineered
mouse models (GEMMs) of cancer entered the arena. Several
different types of GEMMs can be distinguished, each with their
own beneﬁts and limitations (Table 1). In the more advanced
GEMMs, de novo development of ‘‘spontaneous’’ tumors is
triggered by spatio-temporally controlled induction of
mutations in single cells amidst their natural microenviron-
DOI 10.1002/bies.201100018
1) Division of Molecular Genetics, Netherlands Cancer Institute, Amsterdam,
The Netherlands
2) Centre of Biomedical Genetics, Amsterdam, The Netherlands
3) Academic Medical Center, Amsterdam, The Netherlands
4) Division of Molecular Biology, Netherlands Cancer Institute, Amsterdam,
The Netherlands
*Corresponding authors:
Anton Berns
E-mail: A.Berns@nki.nl
Jos Jonkers
E-mail: J.Jonkers@nki.nl
Abbreviations:
ESC, embryonic stem cell; GEMM, genetically engineered mouse model;
GoF, gain-of-function; LoF, loss-of-function; LSL, Lox-STOP-Lox; RMCE,
recombinase mediated cassette exchange.
Bioessays 33: 701–710, 2011 WILEY Periodicals, Inc. www.bioessays-journal.com 701
M
e
t
h
o
d
s
,
M
o
d
e
l
s
&
T
e
c
h
n
i
q
u
e
sment. In this essay, we will not provide an extensive overview
of different GEMMs to date, as this has been expertly reviewed
by others recently [3, 4]. Instead, we will discuss the develop-
ment of a new, more ﬂexible GEMM platform designed to
meet the increasing demand for swift in vivo validation
of potential cancer genes and drug targets identiﬁed in
functional genomics screens and human cancer genome-
sequencing studies [5].
Germline GEMMs: The standard repertoire
GEMMs of human cancers have proven to be valuable models
for gaining insight into the different stages of tumorigenesis
[3]. Many of the inherited cancer syndromes have been mod-
eled in conventional GEMMs carrying engineered germline
mutations in the respective genes. Although conventional
GEMMs proved useful to study the in vivo role of cancer genes,
their utility for modeling cancer has been limited due to
incomplete tumor penetrance coupled with long and highly
variable tumor latency.
Conditional GEMMs
Many of these drawbacks were overcome with the advent of
conditional GEMMs [6], which allowed for tissue-speciﬁc and
time-controlled introduction of conditional mutations using
Cre-loxP site-speciﬁc recombination. In practice, these mice
have been engineered to contain genetic elements ﬂanked by
loxP recombination sites. Depending on their conﬁguration,
recombination between loxP elements by expressing the Cre
recombinase can lead to (mutant) gene activation or inacti-
vation. Tissue-speciﬁc Cre expression is achieved by trans-
genic expression of Cre under control of a tissue-speciﬁc
promoter or by infection of the target tissue with viral vectors
containing a Cre recombinase under control of a ubiquitous or
cell-type speciﬁc promoter. An additional level of control can
be achieved by using CreERT2 transgenes that encode a fusion
protein of Cre and the ligand-binding domain of the estrogen
receptor (ER). Upon treatment of CreERT2 transgenic mice
with the estrogen analog tamoxifen, the CreERT2 recombinase
translocates to the nucleus and catalyzes recombination
of loxP elements, allowing for time-controlled activation of
conditional mutations.
Limitations of conditional GEMMs
Conditional GEMMs can recapitulate the stochastic nature of
sporadic cancer and often develop one particular tumor type.
These models show reduced tumor burden and prolonged
lifespan as compared to conventional GEMMs, and are there-
fore more suitable to study tumor initiation, progression and
therapy response [7]. In addition, conditional mouse models
can be applied for the validation of candidate cancer genes
and drug targets. Unfortunately, a number of logistic and
ﬁnancial barriers prohibit the extensive use of these models
in preclinical and translational research. For instance, con-
ditional GEMMs have a long lead-time to be established and
validated. The whole process of introducing targeted
mutations into embryonic stem cells (ESC) and producing
mouse strains from the engineered ESCs is laborious and
expensive. Often, multiple conditional mutations are required
Table 1. Comparison between various types of genetically engineered mouse models (GEMMs) of cancer
Germline GEMMs Non-germline GEMMs
Conventional
models
Conditional
models
Transplantation
Models [11, 43]
Chimeric
Models [8, 12]
Disease
Cancer type Familial Sporadic Sporadic Sporadic
Cancer development is induced by key driver
mutations found in human tumors
Yes Yes Yes Yes
Cancer develops in relevant tumor
microenvironment
No
a Yes Yes Yes
Cancer develops in immunocompetent host Yes Yes Yes Yes
Cancer displays all relevant clinical stages Usually not Yes Yes Yes
Model characteristics
Rapid cohort generation No No Yes Yes
Possibility for ex-vivo engineering No No Yes Yes
Tumor types that can be modeled Limited by viability
of mouse mutants
Many Limited by availability
of stem/progenitor cells
Many
Investment
Lead-time Long Long Moderate Moderate
Breeding time
b Long Long None None
Overall costs
b High High Moderate Moderate
Utility
Validation of candidate cancer genes Moderate Good, but costly
and time-consuming
Good Good
Validation of drug targets Moderate Good, but costly
and time-consuming
Good Good
a All tissues have the same genetic rearrangements, including the tumor microenvironment, possibly indirectly affecting tumor behavior.
b Estimations for investment in time and relative costs are provided in Figure 4.
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sfor development of a speciﬁc tumor, thus requiring extensive
intercrossing of single mutant mouse strains to produce com-
pound mutant strains of the desired genotype. This process is
space- and time-consuming (because it requires complex
breeding schemes that involve multiple crosses), inefﬁcient
(due to unavoidable generation of offspring with unwanted
genotypes), and expensive.
Non-germline chimeric GEMMs: Modelling
without breeding
A number of the intrinsic drawbacks of germline GEMMs have
been overcome in mosaic mouse models, called non-germline
chimeric GEMMs [4, 8]. These models can be subdivided in
two groups, transplantation models and chimeric models
(Table 1). The transplantation models are generated by
implanting somatic stem or progenitor cells into the respect-
ive adult tissue of a recipient mouse. These transplanted cells
are modiﬁed ex vivo to contain tumor-initiating mutations or
are derived from tissues of tumor-prone mice. This concept is
often used in the hematopoietic system, but has also been
applied for tumors from other tissues, such as breast, brain,
and liver [9–11]. As this approach is dependent on the iso-
lation of stem/progenitor cells, the range of tumor types that
can be modeled is limited by the availability and accessibility
of these cells. Chimeric models do not have this limitation, as
they are based on genetically engineered ESCs carrying all the
essential modiﬁcations needed to develop a particular type of
cancer. The chimeric mice generated with these ESCs are
directly used for tumor induction, allowing for fast cohort
generation without tedious intercrosses. The chimeras have a
mixture of wild-type cells originating from both host blasto-
cysts and genetically modiﬁed cells originating from the cul-
tured ESCs allowing for tumor development in context of
normal tissue, recapitulating human tumorigenesis. The
downside of this approach is again the long lead-time. The
ESCsaremodiﬁed in astep-wisemannerand need to betested
at each individual stage for functionality of the introduced
genetic element and also for their contribution to the sub-
sequent chimeras (Fig. 1A) [8, 12]. With these considerations
in mind we explored an alternative strategy for generating
nongermline chimeric GEMMs that fulﬁll all requirements for
efﬁcient use in translational research. This strategy should
meet the following criteria. Firstly, it should yield mouse
models that represent the human disease, i.e. de novo tumor
development should be driven by key genetic lesions induced
in the relevant target tissue in phenotypically wild-type hosts,
and display the typical clinical stages of tumor progression in
patients.
Secondly, the strategy should allow for rapid ex vivo engin-
eering of ESCs and generation of mouse cohorts, resulting in a
ﬂexible platform for side-by-side evaluation of multiple cancer
genes or drug targets. Thirdly, the approach should be cost-
effective, making it amenable for preclinical and translation
research in academic institutions. Finally, the strategy should
fulﬁll some of the three R’s for animal-based research (Replace,
Reduce and Reﬁne), by reducing the amount of mice required
for breeding and by reﬁning GEMMs to improve their utility as
preclinical in vivo models of human cancer.
GEMM-ESC: The fast-track strategy
As an alternative strategy to produce non-germline chimeric
GEMMs, we propose a two-stage approach, named GEMM-
ESC, which is outlined in Fig. 1B. In the ﬁrst stage, ESCs
are derived from already existing and validated conditional
GEMMs using recently described ESC culture conditions that
ensure maintenance of ESC pluripotency (i.e. the capacity of
ESCs to contribute toeverytissue ofthe developingembryo) [13].
The GEMM-derived ESC clones are injected into pre-implan-
tation embryos and their contribution to the chimeras is
determined. The best performing GEMM-ESC clones are
selected and targeted with recombinase mediated cassette
exchange (RMCE) acceptors in pre-deﬁned loci [14] (for an
example see Fig. 2A).
These RMCE acceptors contain site-speciﬁc recombination
sites (typically FRT sites) that permit (Flp) recombinase-
mediated site-speciﬁc integration of custom-designed
exchange vectors containing compatible recombination sites
(Fig. 2B). These targeted GEMM-ESC clones are again validated
for their contribution to chimeric mice. The best performing
GEMM-ESC clones are expanded and frozen as a repository for
future experiments.
In the second stage, a genetic modiﬁcation (e.g. an indu-
cible shRNA or a conditional cDNA) is introduced into the
RMCE locus of the GEMM-ESC clone of a particular mouse
model (Fig. 2C). The GEMM-ESC clone containing the desired
modiﬁcationisusedtogeneratechimeras,inwhichtumorsare
induced using the same methods as the ones established for
the conditional GEMM from which the ESC clone was derived.
The second stage ensures rapid and ﬂexible generation of
multiple GEMM-ESC clones with gain-of-function (GoF) or
loss-of-function (LoF) alleles for different target genes and
allows for side-by-side comparison of the phenotypic effects
of these alleles on de novo development and maintenance of
sporadic tumors.
GEMM-ESC versus other non-germline chimeric GEMMs
Our GEMM-ESC approach differs in two aspects from the
published non-germline chimeric GEMMs [4, 8]. Firstly, both
published models start with wild-type ESC lines that are
modiﬁed in a step-wise fashion, whereas our GEMM-ESC
method starts with ESC lines that already carry all the genetic
modiﬁcationsrequiredfortumordevelopment.Thiseffectively
eliminates many of the validation steps required for functional
testing of the ESCs at intermittent stages (compare Fig. 1A
and B). The GEMM-ESC approach will also reduce the
cumulative ESC culture period, thereby reducing the risk of
introducing unnoticed mutations.
The second difference between GEMM-ESC and published
models is the method used to introduce genetic modiﬁcations.
In the two published models a classic transgenic approach is
applied, which allows for the quick introduction of genetic
elements in ESCs. The main limitation of this approach is that
it is uncontrolled. Transgenes integrate randomly in the ESC
genome possibly affecting expression of endogenous genes at
or near the integration site. In addition, random integration of
transgenesoftenoccursatmultiplelociaggravatingtheformer
problem. Furthermore, the integrity of randomly integrated
....Prospects & Overviews I. J. Huijbers et al.
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stransgenes is not guaranteed, which is complicated by the fact
that transgenes often integrate as concatemers containing
varying numbers of transgene copies. Although these issues
can be overcome by selection for ESC lines with single or low
copy integrations and proper expression of the transgene [8],
an approach that starts with a single integration into a pre-
deﬁned expression site is highly preferred. It also has the
advantage that it permits for testing of allelic series of a
particular gene.
Stage one: ESC derivation
Selection of appropriate GEMMs for ESC derivation
In principle, any established GEMM can be used as a starting
point for the GEMM-ESCstrategy, although not every model will
beequallysuitable.Forinstance,someconventionalGEMMsare
notpreferredfor ESCderivation because mutations in genes that
controlcellproliferationordifferentiationmayaffectbehaviorof
ECSs during in vitro culture or production of chimeric mice.
Similarly, ESCs derived from mouse mutants with defects in
telomere maintenance or DNA damage repair may show
increased genomic instability, resulting in accumulation of
mutations and genetic variation in individual ESC clones and
theensuing chimeras. Many of these problems can be effectively
avoided by focusing on conditional GEMMs, as the conditional
knockout alleles function normally. Many conditional GEMMs
for human cancers arecurrently available [3]. In our institute we
have characterized and validated conditional GEMMsfor breast,
lung, brain, and skin tumors [15–21]. In Table 2 we have listed a
selection of validated conditional GEMMs that represent good
starting points for derivation of ESC lines. A point of caution
should be made for conditional GEMMs with a Cre recombinase
controlled by a tissue-speciﬁc promoter, e.g. K14-Cre,W A P - Cre,
or Pdx-Cre (Table 2). Although Cre recombinase is normally not
expressed in the germline of these strains, in vitro propagation
of ESCs might cause unwanted recombination of conditional
alleles due to aberrant Cre expression.
Therefore, ESCs derived from such GEMMs should always
be monitored for recombined alleles before further use. The
ﬁnal chimeric mice obtained from these veriﬁed ESC clones
will have similar Cre expression in adult tissues as compared
to the original model and consequently should have similar
tumor characteristics, provided that the ESC clones give rise to
good chimeras.
Figure 1. Non-germline chimeric GEMMs. A: Current method to
obtain non-germline chimeric GEMMs by step-wise modiﬁcation of
wild-type ESCs by introduction of targeted mutations in tumor sup-
pressor genes (TSGs) and random integration of transgenes for dox-
ycycline (DOX) regulatable expression of luciferase reporter and
oncogenes [8, 12]. B: Outline for GEMM-ESC strategy. ESCs are
derived from an existing conditional GEMM containing all the modiﬁ-
cations needed to develop a particular type of tumor. The GEMM-
derived ESC are validated and targeted with a RMCE acceptor
allowing for easy reengineering of the GEMM-ESCs using exchange
vectors containing GoF or LoF alleles. Tumors are induced in chi-
meric animals.
Targeting of
1st TSG allele
DOX-regulatable
luciferase
GEMM-ESC
Targeting of 
RMCE acceptor
GoF
LoF
Reporter
wt ESC
ESC derivation
Targeting of
2nd TSG allele
DOX-regulatable
oncogene
Validated GEMM
Validate ESC:
- correct targeting
- chimerism
Validate ESC:
- correct targeting
 -chimerism
Validate ESC:
- transgene integrity
  and expression
- chimerism
Validate ESC:
- transgene integrity
  and expression
- chimerism
Validate ESC:
- chimerism
Validate ESC:
- correct targeting
 -chimerism
Blastocyst
Induce tumors
Induce tumors
A)
B)
Non-germline chimeric GEMM strategy
GEMM-ESC strategy
RMCE Create cohorts of chimeras
Create cohorts of chimeras
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x
Flpe mediated cassette exchange
Neomycin selection
Creative Region
Homologues Recombination
Hygromycin selection
Rosa26 locus
Targeting vector
RMCE exchange vector
Knock-In allele
LoF vectors:
TetO - shRNA
GoF vectors:
zsgreen HygR SA Flpe
ATG
PGK CAGGS
FRT F3
zsGreen HygR SA Flpe
ATG
PGK CAGGS
x
pA ∆5’ NeoR
shRNA
CAGGS
FRT F3
SA
ATG H1TetO
∆5’ NeoR
shRNA
itetR CAGGS
H1TetO
RMCE exchange vector
pA ∆5’ NeoR
shRNA
itetR CAGGS
FRT F3
itetR
cDNA
SA-pA SA-pA
lox lox
CAGGS
STOP
pA ∆5’ NeoR
tissue-specific
promoter
CreERT2
pA ∆5’ NeoR
Constitutive promoter - LSL - cDNA
  e.g.  - putative oncogene
  -  reporter
Tissue-specific promoter - CreERT2
Figure 2. RMCE as described by Seibler and co-workers [36]. A: The Rosa26 allele is targeted with a cassette encoding the DATG-zsGreen
gene, a Hygromycin resistance (Hyg
R) marker and the FLPe recombinase. Constitutive PGK and CAGGS promoters control the expression of
Hyg
R and FLPe, respectively, whereas expression of zsGreen is controlled by the endogenous Rosa26 gene promoter prior to the F3 recom-
bination site. A FRT recombination site ﬂanks the 30 end of the targeted locus. B: Introduction of doxycycline-inducible shRNA expression
constructs via FLPe recombinase-mediated cassette exchange is achieved by co-transfection of the targeted ESCs with a FLPe expression
plasmid and an RMCE exchange cassette encoding an F3 site, D50 Neomycin resistance (Neo
R) marker, the H1-tet promoter, an shRNA of
choice, the enhanced tet-repressor itetR controlled by the CAGGS promoter and an FRT site. C: The original RMCE exchange vector is ideally
suited for LoF vectors. By replacing the region between the dotted lines, named the creative region, these vectors can be adapted to become
GoF vectors. Two examples are provided, an inducible cDNA and a tissue-speciﬁc CreERT2 gene for spatiotemporal controlled deletion of
genes ﬂanked by loxP sites.
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ESCs are derived from the inner cell mass (ICM) of pre-implan-
tationblastocysts[22].Theyaretypicallyculturedonfeedersof
mitotically inactivated ﬁbroblasts in medium containing leu-
kemia inhibitory factor (LIF), which is required for mainten-
ance of a pluripotent state capable of generating any cell type
in the body [23]. In the last few years it has become clear that
pluripotency of mouse ESCs is governed by three signaling
pathways namely the LIF/STAT3 pathway, the ﬁbroblast
growth factor (FGF)/ERK pathway and the Wnt pathway
[13, 24–27]. These new insights have resulted in the develop-
ment of deﬁned ESC culture media in which feeder cells and
serum have been replaced by small-molecule inhibitors of the
FGF4/ERK and Wnt pathways [13]. These new culture media –
which are known as 2i or 3i medium depending on the number
of inhibitors used – have opened the door for derivation of rat
ESCs [28, 29] and ESCs from mouse strains that were pre-
viously refractory to ESC derivation, such as the CBA and
the MF1 strains [13].
For the GEMM-ESC strategy, we use the new 2i/3i culture
conditions to establish authentic ESCs from conditional
GEMMs. The feasibility of this approach is exempliﬁed by
Nichols and coworkers [30], who used 2i culture medium
supplemented with LIF to derive germline-competent
ESCs from non-obese diabetes (NOD) mice. These ESC
lines had to fulﬁll a number of criteria. Firstly, ESC lines
were veriﬁed for having a normal diploid karyotype and
showing expression of pluripotency markers Nanog and
Oct4. Secondly, their contribution to chimeric mice was
validated and the resulting chimeras were evaluated for
their ability to give germline transmission. The same
parameters were again tested after genetic manipulation
of the NOD ESC lines by introducing a DsRED expression
cassette via PiggyBac transposition. The DsRED positive
NOD ESC clone was indeed able to generate chimeric animals
with germline transmission, validating the entire approach.
We foresee similar efﬁciencies in ESC derivation from
conditional GEMMs, especially since these models are
phenotypically wild-type.
Validation of chimeric mice
One of the most crucial aspects of the GEMM-ESC strategy will
be the validation of the chimeric mice, which should display a
high degree of chimerism and develop tumors with similar
phenotypesandlatenciesastheoriginalGEMM.Thefeasibility
of the GEMM-ESC approach is supported by recent reports on
the successful generation of chimeric mouse models for breast
cancer and non-small cell lung cancer (NSCLC) based on step-
wise introduction of multiple genetic modiﬁcations into wild-
type ESCs [8, 12]. Chimeric mice derived from Ink4a/Arf
-/- ESCs
carrying transgenic constructs for lung-speciﬁc, doxycycline-
inducible expression of mutant HER2
V659E developed doxycy-
cline-inducible lung tumors, which regressed upon doxycy-
cline withdrawal [8]. The tumor burden in these chimeras
correlated with the degree of coat-color chimerism. Longer
tumor latency was observed in the chimeric mice compared to
the conventional mouse mutants, possibly reﬂecting reduced
numbers of premalignant lesions in chimeras due to the pres-
ence of both wild-type and genetically modiﬁed cells. If tumor
penetrance in chimeric mice is too low, despite high degree of
coat color chimerism and effective induction of oncogenic
mutations, completely GEMM-ESC derived F0 mice can be
produced by aggregation of GEMM-ESCs with tetraploid
mouse embryos [31, 32]. Alternatively, chimeric mice can be
bred with the original GEMM to produce GEMM-ESC derived
F1 mice. An advantage of the latter approach is that it
will generate experimental F1 mice as well as control mice
lacking the additional mutation that was introduced in the
GEMM-ESCs.
Stage two: Genetic modification of
GEMM-derived ESCs
Gene targeting in GEMM-derived ESCs
Gene targeting in GEMM-derived ESC lines may be compli-
cated by two factors. One, existing targeting vectors often
have homology arms derived from 129 or C57BL/6 genomic
DNA, as the commonly used mouse ESC lines are derived
from these two inbred strains. However GEMMs have often
been backcrossed to other backgrounds such as FVB/n or
BALB/c. Using the original, non-isogenic targeting constructs
will likely result in reduced gene targeting efﬁciencies due
to the presence of DNA polymorphisms between the ESC
genome and the targeting vector [33]. Therefore, existing
targeting vectors may need to be retroﬁtted with homology
arms isogenic to the appropriate background. In practice,
this means that the strain background of the target locus
in the derived ESCs is determined by screening for
nearby polymorphisms. Upon identiﬁcation of the strain back-
ground a suitable BAC clone is identiﬁed and used for further
manipulations. Alternatively, custom designed homology
arms are ampliﬁed by long-range PCR with a high-ﬁdelity
polymerase, using DNA isolated from the GEMM-ESC as
template.
Table 2. Validated conditional GEMMs suitable for derivation of ESCs
Tumor type Conditional alleles Cre induction Reference
Hereditary breast cancer Brca1
F/F;Trp53
F/F K14-Cre or WAP-Cre [18]
Lobular breast cancer Cdh1
F/F;Trp53
F/F K14-Cre [15]
Small cell lung cancer Rb
F/F ;Trp53
F/F Intratracheal Adeno-Cre [19]
Non-small cell lung cancer LSL-Kras
G12D Intratracheal Adeno-Cre [44]
Mesothelioma Nf2
F/F;Trp53
F/F;Ink4a
-/- Intrathoracic Adeno-Cre [17]
Pancreatic cancer LSL-Kras
G12D LSL-Trp53
R172H Pdx-Cre [45, 46]
Melanoma LSL-Braf
V600E;Ink4a
-/- Tyrosinase-CreERT2 [47]
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cation of GEMM-derived ESCs is the fact that gene targeting by
homologous recombination has not yet been tested in mouse
ESC lines derived in 2i/3i culture medium. Nonetheless, we do
not expect extensive difﬁculties as it has recently been shown
that a rat ESC line derived in 3i culture medium permits
targeting of the Trp53 gene albeit with a low efﬁciency of
1–4% [34]. Of note, only a single targeting event in the
GEMM-derived ESCs is required to introduce the recombi-
nase-mediated cassette exchange (RMCE) vector. All sub-
sequent manipulations are independent of homologous
recombination (Fig. 2).
Re-engineering of GEMM-ESCs by recombinase
mediated cassette exchange
Recombination-mediated cassette exchange is a technique
that allows for efﬁcient and scalable engineering of the mouse
genome [35]. This strategy involves the exchange of a genomic
region ﬂanked by heterotypic recombination sites (e.g. wild-
type and mutant FRT sites) with an incoming region that is
ﬂanked by the same two recombination sites (Fig. 2A, B). In
cultured ESCs, efﬁcient selection of clones with the correct
recombination event is assured by a switch in antibiotic
resistance.
For instance, Seibler and coworkers used an RMCE system
in which a hygromycin resistance marker ﬂanked by wild-type
and mutant FRT recombination sites was replaced by a neo-
mycin resistance gene ﬂanked by the same recombination
sites following expression of Flp recombinase [36]
(Fig. 2A, B). In addition to the neomycin resistance gene a
doxycycline-inducible shRNA expression cassette was also
introduced.
A major beneﬁt of this approach is that a single intact copy
integration is achieved into a predeﬁned genomic region, effec-
tively creating a knock-in allele. Furthermore, RMCE requires
only a single targeting of ESC clones with the acceptor cassette,
in general a slow and laborious process. All subsequent re-
engineering steps are achieved by simple co-transfection of
ESCs with a custom-designed RMCE vector and also the Flp
expression vector. In principle any locus can be used for recom-
binase-mediatedtargeting.Twolocihavebeenextensivelyused,
i.e. Rosa26 and ColA1 [36, 37]. Both loci have been shown to
allow for ubiquitous expression of the transgene.
Introduction of designer alleles
The ﬂexibility to introduce different genetic elements in the
RMCE locus is very high (Figs. 2C and 3). GoF alleles can easily
be introduced by placing a cDNA of interest under control of a
constitutive or tissue-speciﬁc promoter. An additional level of
control can be obtained by placing a Lox-STOP-Lox (LSL)
Figure 3. Generation of repositories of RMCE-compatible ESCs from
various GEMMs and collections of GoF and LoF vectors enables
rapid in vivo validation of candidate cancer genes and drug targets
identiﬁed in functional genomics screens or cancer genome
sequencing projects [5]. Collections of RMCE-compatible reporter
vectors permit in vivo monitoring of tumor-related processes via non-
invasive imaging techniques.
   GEMM-ESCs
─ Breast cancer
─ Lung cancer
       ◦ SCLC
       ◦ NSCLC
─ Mesothelioma
─ Melanoma
─ Pancreatic cancer
   GoF vectors
─ (mutant) cDNA
─ LSL - (mutant) cDNA
─ TetO - (mutant) cDNA
─ Constitutive promoter
─ Tissue-specific promoter
   LoF vectors
─ shRNA
─ LSL - shRNA
─ TetO - shRNA
─ Constitutive promoter
─ Tissue-specific promoter
   Reporter vectors
─ Tumor volume
─ Proliferation
─ Apoptosis
─ Metabolism
─ Cell Cycle
─ Pathway activity
─ Lineage tracing
Candidate cancer genes Drug targets Therapeutics
Cancer genome sequencing
Fuctional genomics
Repositories of RMCE compatible GEMM-ESCs and vectors
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scassette containing a transcriptional terminator between the
promoter and the cDNA, which will ensure expression of the
cDNA only in cells expressing functional Cre recombinase.
Attractive cDNAs are for instance putative oncogenes, mutant
forms of known oncogenes and CreERT2 constructs for tamox-
ifen-inducible tissue-speciﬁc recombinase expression.
RMCE also permits rapid introduction of various reporter
constructs for non-invasive and longitudinal monitoring of
tumor volume, for tumor lineage tracing and for molecular
imaging of cellular processes such as metabolic activity, pro-
liferation, apoptosis, and the activity of speciﬁc signaling
pathways. Introduction of reliable reporters for tumor growth
will be of immediate interest, as many conditional GEMMs for
internal cancer types would beneﬁt from improved tumor
monitoring. Such reporters may include codon-optimized ﬁre-
ﬂy luciferase for non-invasive imaging or ﬂuorescent proteins
for intravital imaging of tumor cells using two photons or
Figure 4. Side-by-side comparison for investment in time and costs
between conventional targeting in wild-type ESCs and the GEMM-
ESC approach. A typical example is given for a tumor model with
four modiﬁed alleles, i.e. Rb
F/F;Trp53
F/F, in which one additional
allele is introduced, a luciferase reporter. A conditional luciferase
expression construct is introduced in wild-type ESCs or Rb
F/
F;Trp53
F/F ESCs via either classic targeting or RMCE, respectively.
Both approaches require blastocyst injections, though the GEMM-
ESCs require more injections to directly establish a cohort of F0
chimeras. For the conventional wild-type ESC approach the number
of crosses is shown to establish a similar cohort of compound
mutant mice of the desired genotype. The ratio of mice with the right
genotype generated from each cross is indicated. Note that the
GEMM-ESC approach will deliver a considerable gain in time to
establish a cohort (approximately 14 months), and a reduction in
costs as the initial higher costs for chimera production are gained
back by the absence of any breeding.
wt ESC RbF/F; Trp53F/F ESC
fLuciferase lox lox
CAGGS
STOP
albino wt Luc+ chimera (#1-6)
x
RbF/F; Trp53F/F Luc+; RbF/-; Trp53F/-
x
Luc+; RbF/F; Trp53F/F RbF/F; Trp53F/F
x
Luc+; RbF/F; Trp53F/F chimeric cohort
Luc+; RbF/F; Trp53F/F cohort
fLuciferase lox lox
CAGGS
STOP 1
2
3
4
5
6
8
12
16
1 in 8
1 in 2
h c a o r p p a   C S E - M M E G h c a o r p p a   C S E   l a n o i t n e v n o C
months
E C M R g n i t e g r a T
costs
€€€€ €
€ €
€
€€
€€
4 sessions x 3 fosters = 12 fosters
12 fosters x 4 pups = 48 pups, of which on average 24 chimeras
1 session x 3 fosters = 3 fosters
3 fosters x 4 pups = 12 pups, of which on average 6 chimeras
determine germline transmission 6 chimeras
F1:       #1            #2            #3             #4            #5             #6
Luc+ chimera (1 & 2) RbF/F; Trp53F/F x
20
€
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smultiphoton microscopy [38, 39]. The ﬂexibility for side-by-
side comparison of different ﬂuorochromes or luminescence
markers in speciﬁc tumors in chimeric mice will facilitate
identiﬁcation of the most optimal reporter for each individual
GEMM-ESC tumor model.
LoF alleles can also be introduced by RMCE, by employing
constructs for constitutive or tissue-speciﬁc expression of
shRNA. An additional level of control can be achieved by
using the Tet-ON or Tet-OFF system for doxycycline- regulat-
able expression of shRNAs. An RMCE cassette is available for
doxycycline-regulatable shRNA expression in the Rosa26
locus [36] (Fig. 2A, B). The utility of inducible shRNA expres-
sion for in vivo drug target validation was demonstrated by
Xue and co-workers, who used a doxycycline-regulatable
shRNA against Trp53 to establish a chimeric mouse model
of liver cancer [40]. Discontinuing shRNA expression by dox-
ycycline administration to mice with established liver tumors
caused P53 reactivation and concomitant tumor regression.
Potential drawbacks of the GEMM-ESC approach
We foresee that the use of RMCE in GEMM-ESCs will create a
ﬂexible and rapid in vivo platform for side-by-side comparison
of potential cancer genes and drug targets. Nevertheless, we
also foresee potential drawbacks of the GEMM-ESC approach.
One limitation is that it can only be used for tumor intrinsic
modiﬁcations, since the study of tumor extrinsic elements is
difﬁcult to model in a non-germline chimeric setting as wild-
type stromal cells will likely compensate for the effects of the
modiﬁed allele in for instance mesenchymal or endothelial
cells.
A second drawback for the chimeric GEMM-ESC models is
that they will not alwaysbe directly comparable to the original
model in terms of tumor incidence and latency. How they
compare needs to be determined on a model-to-model basis.
We anticipate that comparable tumor latencies will be
observed for models with single, clonal tumors, whereas
models with multiple, oligoclonal tumors may yield GEMM-
ESC chimeras with prolonged latencies due to lower tumor
burden. On the ﬂip side the GEMM-ESC approach may allow
for improved side-by-side comparison of cancer genes due to
elimination of genetic background differences and associated
phenotypic variation arising from modiﬁer loci introduced via
intercrosses.
Another aspect of the GEMM-ESC approach that needs to
be assessed is the correlation between the observed coat color
chimerism and the real chimerism in the tissue of interest.
Experimentally, a ratio can be established by introducing a
ﬂuorescent marker in the ESCs to determine the ratio of ﬂuor-
escent versus non-ﬂuorescent cells in the target tissue in
chimeric mice. This approach will allow the determination
of a cut-off point for the use of chimeras. Ideally, the GEMM-
ESC approach would use F0 mice that are fully derived from
ESCs. Several injection techniques have been established to
achieve this goal [31, 32, 41].
A ﬁnal limitation for the general use of the GEMM-ESC
approach is the dependence on specialized facilities to pro-
duce the F0 chimeras or ESC derived mice. Many institutes
have core facilities for mouse blastocysts injections, and the
injectionofGEMM-ESCclonesisnodifferentfromtheinjection
of wild-type ESC clones. Only the injection capacity needs to
be increased to meet the demand.
Conclusions
The power of the GEMM-ESC approach lies in the fact that it
starts from well-established GEMMs, taking advantage of the
time that has already been invested in characterizing, validat-
ingandoptimizingthesemodels.GenerationofGEMM-derived
ESCs will create a cumulative repository that permits easy
distribution of these preclinical models to the wider scientiﬁc
communityandprovidesanalternativeforcryopreservationof
mouse strains by embryo or sperm freezing (Fig. 3). Should the
GEMM-ESC approach live upto its promiseit will revolutionize
the way we work with GEMMs. Currently, a large proportion of
genetically engineered mice in animal facilities are kept for
breeding purposes to maintain the various strains and only
a minority is used in experiments (Fig. 4). The GEMM-ESC
approach will result in a substantial reduction of breeding
colonies over time. Initially, breeding pairs of a speciﬁc GEMM
are required for derivation of ESCs, but once this is accom-
plished the emphasis will shift towards generating chimeric
animals from GEMM-ESCs carrying various additional modi-
ﬁcations. These chimeric mice will be directly used for in vivo
experiments. In addition, the GEMM-ESC approach will facili-
tate the use of complex GEMMs in cancer research as the
introduction of additional modiﬁcations is greatly simpliﬁed
due to the RMCE approach in GEMM-derived ESCs. The
researcher only needs to customize the exchange vector and
introduce this in the ESCs (Fig. 2C and 3).The modiﬁed ESCs
are subsequently used for the production of chimeric mice by
injection into pre-implantation embryos. The next few years
will be crucial to assess whether the GEMM-ESC strategy will
be a valid alternative to the current approaches to model
cancer in GEMMs. The ﬁrst proof-of-concept of the GEMM-
ESC approach has recently been published [42].
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